The School of Pharmacy at the University of Nottingham is looking for high calibre, international students to join its new Doctoral Training Centre in Pharmaceutical Sciences for International Students (DTCi). Applicants will have a good degree in a relevant discipline (e.g. pharmacy, chemistry, cell biology, biochemistry, etc) and fulfil our English language entry criteria. All successful applicants will receive support for laboratory expenses and most will be using our innovative electronic laboratory notebook. Below is a list of potential PhD projects offered by our research groups. You'll find more details by clicking on each title. In certain cases, one-year MRes projects may be based on similar research topics. More information is available from www.nottingham.ac.uk/Pharmacy/ProspectiveStudents/Postgraduates/DTCi.aspx.
For all of these projects, you'll need to pay your own tuition fees and living costs. For certain students the School of Pharmacy offers support for living expenses through its DTCi enhancement fund. Scholarship support may also be available via the International Office.
|Dr P Gershkovich||The role of life style and co-morbidities in statin-induced muscle toxicity|
|Dr P Gershkovich||Targeting cannabinoids to the gut-associated lymphoid tissue (GALT) for improved treatment of autoimmune diseases|
|Dr P Gershkovich||Targeting protease inhibitors to the gut-associated lymphoid tissues for improved treatment of HIV/AIDS|
|Dr P Gershkovich||Pharmacokinetics and pharmacodynamics of cordycepin, a potential lead drug in osteoarthritis|
|Dr D Heery||Chromatin Regulators in Cancer|
|Dr D Heery||Nuclear Receptors and their Coactivators in Cancer|
|Dr D H Kim||A metabolomic investigation into the effects of allergic sensitisation on human dendritic cells|
|Dr A Piccinini|
Prof D Heery
|Regulation of gene expression at the intersection of infection, inflammation and cancer|
|Dr M D Smith||HEAT: The Helicobacter Eradication Aspirin Trial|
|Dr L White||Combining stem cell and drug delivery to modulate macrophage phenotype toward M2 in spinal cord injury|